JP5845240B2 - Gold wire continuous fermentation product, production method and use thereof - Google Patents

Gold wire continuous fermentation product, production method and use thereof Download PDF

Info

Publication number
JP5845240B2
JP5845240B2 JP2013260261A JP2013260261A JP5845240B2 JP 5845240 B2 JP5845240 B2 JP 5845240B2 JP 2013260261 A JP2013260261 A JP 2013260261A JP 2013260261 A JP2013260261 A JP 2013260261A JP 5845240 B2 JP5845240 B2 JP 5845240B2
Authority
JP
Japan
Prior art keywords
group
mice
gold
fermentation product
gold wire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013260261A
Other languages
Japanese (ja)
Other versions
JP2015080477A (en
Inventor
謝長奇
黄宜綸
蔡沂瑾
黄俊智
葉文麗
林明輝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tunghai University
Original Assignee
Tunghai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tunghai University filed Critical Tunghai University
Publication of JP2015080477A publication Critical patent/JP2015080477A/en
Application granted granted Critical
Publication of JP5845240B2 publication Critical patent/JP5845240B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

本発明は、機能性発酵産物に関し、特に金線連発酵産物、その製造方法および用途に関する。   The present invention relates to a functional fermentation product, and more particularly, to a gold wire continuous fermentation product, a production method thereof, and an application.

近年、ライフスタイルの変化より、多くの人は、自宅で食事を取るという食習慣から、少なくとも2食が主に外食となる食習慣へ変化した。外食を長期間続けた結果、野菜の摂取量が減り、肉類の摂取量が増えるという傾向がある。これにより、栄養バランスの偏りをもたらすだけでなく、多くの外食、例えば、フライドチキンや清涼飲料水などは、油、糖質、塩分の含有量が多いため、カロリーの過剰摂取により肥満やメタボリックシンドロームなどの問題になり、さらに、個人の健康に影響を与える。高カロリー食品の摂りすぎにより肥満だけではなく、肝臓に脂肪がたまりすぎると、肝臓は正常な脂肪代謝の役割を果たせなくなり、過剰の脂肪を処理できないため、脂肪肝になる傾向がある。   In recent years, due to lifestyle changes, many people have changed from eating habits to eat at home to eating habits where at least two meals are mainly eating out. As a result of eating out for a long time, the intake of vegetables tends to decrease and the intake of meat increases. This not only results in a biased nutritional balance, but many eating outs, such as fried chicken and soft drinks, have a high content of oil, sugar and salt, so obesity and metabolic syndrome due to excessive intake of calories. It will cause problems such as, and will further affect the health of individuals. Not only obesity due to excessive intake of high-calorie foods, but too much fat in the liver tends to become fatty liver because the liver cannot play the role of normal fat metabolism and cannot process excess fat.

一般に、体内に脂肪含量が一定の程度以上高い場合は肥満という。肥満の定義は、時間と場所によって変化する。世界保健機関は、身体質量指数(BMI)を肥満の判断基準として、2012年に公表した報告書において、過体重を身体質量指数が25以上、肥満を身体質量指数が30以上として定義する。肥満の始まりは、体の見た目のみが変わっているため、肥満を慢性病であることがよく軽視される。実際に、肥満が人間に対する影響は、見た目だけではなく、非感染性疾患の罹患率および死亡率の増加につながり、生活の質が低下する。詳細には、体が肥満または過体重の基準に達すると、体内の生理機能に異常が起こる。例えば、異常なインスリン分泌は、体内の脂肪代謝の異常を引き起こすことにより、直接または間接に2型糖尿病、高血圧、高脂血症、非アルコール性脂肪肝、癌、痛風、胆嚢炎、変形性関節症などのような疾病を起こし、そのうち、特に2型糖尿病と肥満との関連性が最も深い。世界保健機関が2012年に公表した報告書において、世界人口のうち12%が肥満症を患い、過体重および肥満が死亡リスクに関連する危険因子の世界第5位であることを明確に指摘した。   In general, when the fat content in the body is higher than a certain level, it is called obesity. The definition of obesity varies with time and place. The World Health Organization defines body mass index (BMI) as a criterion for obesity, and in a report published in 2012, defines overweight as body mass index 25 or more and obesity as body mass index 30 or more. Since the beginning of obesity changes only the appearance of the body, it is often neglected that obesity is a chronic disease. In fact, the effect of obesity on humans not only looks but leads to an increase in morbidity and mortality of non-infectious diseases, resulting in a decrease in quality of life. Specifically, when the body reaches the standard for obesity or overweight, abnormalities in the body's physiology occur. For example, abnormal insulin secretion can cause abnormal fat metabolism in the body, directly or indirectly, type 2 diabetes, hypertension, hyperlipidemia, nonalcoholic fatty liver, cancer, gout, cholecystitis, degenerative joints In particular, type 2 diabetes and obesity are most closely related. A report published in 2012 by the World Health Organization clearly pointed out that 12% of the world's population suffers from obesity and that overweight and obesity are the world's fifth risk factors related to mortality risk. .

肥満は、人間の健康および見た目に大きな影響を与え、故に、いかに予防や治療するかが、現在医学上の研究の課題である。肥満の予防として、長期の食事制限および良い運動習慣を維持すれば、肥満を予防または治療するのに有効だとみなされる。しかし、肥満症患者にとって長期の食事制限および良い運動習慣を維持するのが難しく、単に食事および運動により、なかなか体重コントロールに成功できない。現在、臨床的に最も効果的な肥満の治療方法として胃バイパス手術が存在する。しかし、手術は侵襲的治療であるため、患者自身に対して極めて高いリスクとなり、全ての肥満者に幅広く適用することができない。そのため、手術のほかには、市販の様々なダイエット薬がある。違法薬物が人間の健康に深刻な影響を与えることはともかく、台湾保健省が認可された塩酸フェニルプロパノールアミン(PPA)は、新陳代謝を促進し、カロリー消費量を高めるなどの効果があっても、交感神経作用薬であるため、用量の通りに服用しても、一般的な口渇、動悸、めまいおよび他の副作用に加えて、脳卒中になるリスクも高くなる。   Obesity has a major impact on human health and appearance, and therefore how to prevent and treat is currently the subject of medical research. As obesity prevention, maintaining long-term dietary restrictions and good exercise habits are considered effective in preventing or treating obesity. However, it is difficult for obese patients to maintain long-term dietary restrictions and good exercise habits, and it is difficult to control weight by simply eating and exercising. Currently, gastric bypass surgery exists as the most clinically effective method for treating obesity. However, because surgery is an invasive treatment, it poses a very high risk to the patient himself and cannot be widely applied to all obese people. Therefore, besides surgery, there are various commercially available diet drugs. Regardless of the serious effects of illegal drugs on human health, phenylpropanolamine hydrochloride (PPA), approved by the Taiwan Health Ministry, promotes metabolism and increases calorie consumption. Because it is a sympathomimetic drug, taking it as a dose increases the risk of stroke as well as general dry mouth, palpitation, dizziness and other side effects.

西洋薬または侵襲的治療による副作用を避けるため、多くの研究が漢方薬へ発展している傾向がある。そのうち、「薬王」と呼ばれる金線連(Anoectochilus spp.)は、現在数多い文献研究の重心とされている。金線連は、ラン科の植物であって、全草が漢方薬の材料として珍重されており、人類の各種疾病の治療によく使用されている。現在、金線連における認定された効果が数多く、例えば、台湾特許第I369207号、台湾特許第I379688号および台湾特許出願第09810042号には、金線連抽出物が肝臓保護、抗骨粗鬆症剤、抗炎症、抗アレルギーなどの効果が開示されている。日本特許出願特願平8−302556号および特願2001−263528号は、それぞれ、金線連の抽出物が血糖降下およびダイエットの効果を有すると開示されている。上述より、人体に対して金線連が確実に多くの作用を有することが知られている。しかし、今までの研究は、抽出法により金線連の抽出物を得てから、当該金線連の抽出物を医薬組成物に応用するが、抽出により金線連の抽出物を得る方法は、以下の欠点がある。   Many studies tend to develop into traditional Chinese medicines to avoid side effects from Western medicine or invasive treatments. Among them, the “Anoectochilus spp.” Called “Yakuo” is currently regarded as the center of gravity for many literature studies. The gold line is a plant of the orchid family, and the whole plant is prized as a material for herbal medicine, and is often used for the treatment of various diseases of mankind. At present, there are many recognized effects in the gold wire ream, such as Taiwan Patent No. I369207, Taiwan Patent No. I379688 and Taiwan Patent Application No. 09810042, in which the gold wire ream extract is used for liver protection, anti-osteoporosis agent, Effects such as inflammation and anti-allergy are disclosed. Japanese Patent Application No. 8-302556 and Japanese Patent Application No. 2001-263528 disclose that extracts of gold wire reams have a hypoglycemic and dietary effect, respectively. From the above, it is known that the gold wire ream surely has many actions on the human body. However, until now, research has obtained an extract of the gold wire series by the extraction method, and then the extract of the gold wire series is applied to the pharmaceutical composition. Have the following disadvantages.

1.抽出法では有機溶剤を抽出媒体としてよく使用するため、抽出物に毒性成分を含ませ、人体に対して副作用をもたらす。   1. In the extraction method, an organic solvent is often used as an extraction medium, so that the extract contains a toxic component and causes side effects on the human body.

2.抽出物に有機溶剤などの毒性成分を含ませないように、現在、水を抽出媒体とするものが存在している。しかし、抽出過程において高温処理工程が含まれるため、毒性成分を水に溶解させるため、抽出物に有害物質が含まれる。   2. In order to prevent the extract from containing toxic components such as organic solvents, there is currently an extract using water as an extraction medium. However, since an extraction process includes a high-temperature treatment step, toxic components are dissolved in water, so that the extract contains harmful substances.

3.抽出により得られた抽出物は、その活性成分の含量を向上することができないため、産業上の利用可能性を満たすことが困難である。   3. Since the extract obtained by extraction cannot improve the content of the active ingredient, it is difficult to satisfy industrial applicability.

本発明の主な目的は、血糖降下、肥満症の治療またはメタボリックシンドローム、脂肪肝の治療および糖尿病の治療に用いることにより、薬学的に許容される担体または賦形剤と組み合わされて医薬組成物が調製され、少なくとも1つの食品組成物と混合されて疾病予防および健康維持のための食品が形成されうる、金線連発酵産物を提供することにある。   The main object of the present invention is to use a pharmaceutical composition in combination with a pharmaceutically acceptable carrier or excipient by use in hypoglycemia, obesity treatment or metabolic syndrome, fatty liver treatment and diabetes treatment. Is prepared and mixed with at least one food composition to provide a food product for continuous fermentation that can be used to form a food for disease prevention and health maintenance.

医薬組成物として用いられる場合には、その剤型が限定されず、必要に応じて適切に変更可能であり、例えば、丸剤、粉末状、液状、噴霧状、コロイド状、錠剤、懸濁液などの形で提供される。さらに、全体的な味と外観を変更するために、調味剤、甘味料または着色剤を添加することができる。   When used as a pharmaceutical composition, the dosage form is not limited and can be appropriately changed as necessary. For example, pill, powder, liquid, spray, colloid, tablet, suspension Provided in the form of In addition, seasonings, sweeteners, or colorants can be added to alter the overall taste and appearance.

また、食品として用いられる場合には、その食べ方および形態も限定されず、例えば、飲料、咀嚼錠、経口錠剤、スプレー、懸濁液などの形で提供される。   Moreover, when using as a foodstuff, the eating method and form are also not limited, For example, it provides with forms, such as a drink, a chewing tablet, an oral tablet, a spray, a suspension.

本発明のもう1つの目的は、生産コストを有効的に削減するとともに、金線連発酵産物を大量に生産する金線連発酵産物の製造方法を提供することにある。   Another object of the present invention is to provide a method for producing a gold wire continuous fermentation product that effectively reduces production costs and produces a large amount of gold wire continuous fermentation products.

具体的には、本発明の1つの好ましい実施例に開示される金線連発酵産物は、その組成が次式(I)に示す、少なくとも1つの金線連配糖体を含む。

Specifically, the wire continuous fermentation product disclosed in one preferred embodiment of the present invention includes at least one wire continuous glycoside whose composition is represented by the following formula (I).

本発明の第2の好ましい実施例に開示される金線連発酵産物は、血糖降下用の医薬組成物を製造する用途に用いられ、そのうち、前記金線連発酵産物は、少なくとも上式(I)に示すような金線連配糖体を含む。   The gold wire continuous fermentation product disclosed in the second preferred embodiment of the present invention is used for the production of a pharmaceutical composition for hypoglycemia, wherein the gold wire continuous fermentation product is at least represented by the above formula (I). ) Including gold-linked glycosides.

本発明の第3の好ましい実施例に開示される金線連発酵産物は、肥満症治療用の医薬組成物を製造する用途に用いられ、そのうち、前記金線連発酵産物は、少なくとも上式(I)に示すような金線連配糖体を含む。   The continuous wire fermentation product disclosed in the third preferred embodiment of the present invention is used for producing a pharmaceutical composition for the treatment of obesity, wherein the continuous wire fermentation product has at least the above formula ( Gold-linked glycosides as shown in I) are included.

本発明の第4の好ましい実施例に開示される金線連発酵産物は、脂肪肝治療用の医薬組成物を製造する用途に用いられ、そのうち、前記金線連発酵産物は、少なくとも上式(I)に示すような金線連配糖体を含む。   The gold wire continuous fermentation product disclosed in the fourth preferred embodiment of the present invention is used for the production of a pharmaceutical composition for the treatment of fatty liver, of which the gold wire continuous fermentation product has at least the above formula ( Gold-linked glycosides as shown in I) are included.

本発明の第5の好ましい実施例に開示される食品は、前記金線連発酵産物と少なくとも1つの食品組成物とを含み、そのうち、前記金線連発酵産物は、少なくとも上式(I)に示すような金線連配糖体を含む。   A food product disclosed in a fifth preferred embodiment of the present invention includes the gold wire continuous fermentation product and at least one food composition, wherein the gold wire continuous fermentation product is at least represented by the above formula (I). Includes gold-linked glycosides as shown.

本発明の第6の好ましい実施例に開示される金線連発酵産物の製造方法は、以下のステップを含む。   The method for producing a continuous wire fermentation product disclosed in the sixth preferred embodiment of the present invention includes the following steps.

ステップa:乳酸菌と金線連培地とを発酵反応させる。   Step a: Fermentation reaction of lactic acid bacteria and gold wire continuous medium.

ステップb:ステップaで得られた発酵液により金線連発酵産物を得た。   Step b: A gold wire continuous fermentation product was obtained from the fermentation broth obtained in step a.

前記ステップaにおける前記乳酸菌は、ラクトバチルス・カゼイ・サブスピーシーズ・ラムノサス(Lactobacillus casei subsp. Rhamnosus)、LGG(Lactobacillus rhamnosus G.G.)またはラクトバチルス・プランタラム(Lactobacillus plantarum)である。   The lactic acid bacterium in step a is Lactobacillus casei subsp.

ステップaで行われる発酵反応の条件は、温度が25〜42℃、pH値が4.0〜7.0、撹拌速度が0〜100rmpである。   The conditions for the fermentation reaction performed in step a are a temperature of 25 to 42 ° C., a pH value of 4.0 to 7.0, and a stirring speed of 0 to 100 rpm.

ステップbにおける前記発酵液が滅菌および遠心分離されて、前記金線連発酵産物を得る。   The fermentation broth in step b is sterilized and centrifuged to obtain the gold wire continuous fermentation product.

金線連配糖体標準品の逆相高速液体クロマトグラフを示す図である。It is a figure which shows the reverse phase high performance liquid chromatograph of a gold wire continuous glycoside standard goods. 金線連配糖体標準品の検量線を示す図である。It is a figure which shows the calibration curve of a gold wire continuous glycoside standard goods. 未発酵の金線連の逆相高速液体クロマトグラフを示す図である。It is a figure which shows the reverse phase high performance liquid chromatograph of an unfermented gold wire line. LcR金線連配糖体標準品の逆相高速液体クロマトグラフを示す図である。It is a figure which shows the reverse phase high performance liquid chromatograph of LcR gold wire continuous glycoside standard goods. 異なる処理による各群のマウスの体重変化を示す図である。It is a figure which shows the body weight change of the mouse | mouth of each group by a different process. 各群のマウスの腎臓周囲脂肪組織重量を示す図である。It is a figure which shows the perirenal fat tissue weight of the mouse | mouth of each group. 各群のマウスの精巣周囲脂肪組織重量を示す図である。It is a figure which shows the testicular fat tissue weight of the mouse | mouth of each group. 各群のマウスの脂肪組織重量を示す図である。It is a figure which shows the fat tissue weight of the mouse | mouth of each group. 異なる処理による各群のマウスの体重変化を示す図である。It is a figure which shows the body weight change of the mouse | mouth of each group by a different process. 各群のマウスの肝臓重量を示す図である。It is a figure which shows the liver weight of the mouse | mouth of each group. A乃至Cは、第1群〜第3群のマウスから取り出した肝臓を示す図である。FIGS. 3A to 3C are diagrams showing livers taken out from mice of the first group to the third group. FIGS. A乃至Cは、第1群〜第3群のマウスの肝臓組織切片をヘマトキシリン/エオシンで組織染色を行った結果を示す図である。FIGS. 4A to 4C are diagrams showing the results of tissue staining of hepatoxylin / eosin on liver tissue sections of mice of Group 1 to Group 3. FIG. A乃至Cは、第1群〜第3群のマウスの肝臓組織切片を4−ヒドロキシノネナールで免疫組織染色を行った結果を示す図である。FIGS. 4A to 4C are diagrams showing the results of immunohistochemical staining of liver tissue sections of mice of Group 1 to Group 3 with 4-hydroxynonenal. A乃至Eは、第1群〜第5群のマウスの肝臓組織切片におけるインスリン受容体の免疫組織染色の結果を示す図である。A to E are diagrams showing the results of immunohistochemical staining of insulin receptor in liver tissue sections of mice of Group 1 to Group 5. A乃至Eは、第1群〜第5群のマウスの肝臓組織切片におけるグルコース輸送体の免疫組織染色の結果を示す図である。A to E are diagrams showing the results of immunohistochemical staining of glucose transporters in liver tissue sections of mice of Group 1 to Group 5.

以下、実施例を挙げて本発明をさらに具体的に説明するが、下記実施例は本発明の内容を例示するためのものに過ぎない。本発明の明細書および特許請求の範囲は、これらの例によって限定されるものではない。   Hereinafter, the present invention will be described more specifically with reference to examples. However, the following examples are only for illustrating the contents of the present invention. The specification and claims of the present invention are not limited by these examples.

実施例1:
金線連培地を取って発酵槽に置き、前記金線連培地に適量のラクトバチルス・カゼイ・サブスピーシーズ・ラムノサスを接種し、発酵槽において、撹拌速度が0〜100rmp、温度が25〜42℃、pH値が4.0〜7.0の状態で、発酵培養を行う。培養が完了した後、発酵液を取って滅菌および遠心分離を行って、LcR金線連発酵産物を得た。
Example 1:
Take the gold wire continuous medium and place it in a fermenter, inoculate the gold wire continuous medium with an appropriate amount of Lactobacillus casei, subspecies, and rhamnosus. Fermentation culture is performed at a pH value of 4.0 to 7.0. After completion of the culture, the fermentation broth was taken and sterilized and centrifuged to obtain an LcR gold continuous fermentation product.

また、上記調製工程に基づいて、LGGおよびラクトバチルス・プランタラムのそれぞれと、前記金線連培地と発酵反応をさせ、LrG金線連発酵産物と、Lp金線連発酵産物とをそれぞれ得た。   Moreover, based on the said preparation process, each LGG and the Lactobacillus plantarum, and the said gold wire continuous culture medium were made to ferment, and the LrG gold wire continuous fermentation product and the Lp gold wire continuous fermentation product were obtained, respectively. .

実施例2:金線連配糖体標準品の定性定量。   Example 2: Qualitative quantification of gold-linked continuous glycoside standard product.

金線連配糖体標準品を取って、逆相高速液体クロマトグラフィーのカラム(Mightysil ODS,4.6×250mm,5μm,ELSD detector)により、移動相として純水/アセトニトリルが98.5:1.5、流量が0.2ml/min、カラム温度が室温の状態で分析する。結果は図1に示すように、金線連配糖体標準品の滞留時間が約22.895分であることが分かった。   A gold-linked glycoside standard product was taken, and pure water / acetonitrile as a mobile phase was 98.5: 1 using a reversed-phase high performance liquid chromatography column (Mightysil ODS, 4.6 × 250 mm, 5 μm, ELSD detector). .5, Analysis is performed with the flow rate of 0.2 ml / min and the column temperature at room temperature. As a result, as shown in FIG. 1, it was found that the residence time of the gold wire continuous glycoside standard product was about 22.895 minutes.

次いで、適量の金線連配糖体をそれぞれ取り、水で標準溶液を配合し、各前記金線連配糖体の水溶液の質量濃度が100〜400mcg/ml、試料注入量が10μLで、化合物のピーク面積比を縦軸にし、金線連配糖体標準品の試料注入量を横軸にして標準曲線を作成する。結果は表1および図2に示すように、回帰式:Y=817.53X−73981,R=0.9967が得られた。 Next, an appropriate amount of each gold-linked glycoside is taken, and a standard solution is blended with water. A standard curve is prepared with the peak area ratio of the vertical axis as the vertical axis and the sample injection amount of the gold-linked continuous glycoside standard product as the horizontal axis. As a result, as shown in Table 1 and FIG. 2, the regression equation: Y = 817.53X-73981, R 2 = 0.9967 was obtained.

表1は、金線連配糖体標準品の質量濃度と測定ピーク値を示す。 Table 1 shows the mass concentration and the measurement peak value of the gold-linked continuous glycoside standard product.

実施例3:金線連発酵産物は大量の金線連配糖体を含む。   Example 3: Gold wire continuous fermentation product contains a large amount of gold wire continuous glycosides.

実施例1で得られたLcR金線連発酵産物および未発酵の金線連を取って、それぞれ、実施例2における条件で逆相高速液体クロマトグラフィーのカラムにより分析を行った。結果は図3および図4に示すように、そのうち、図3は、未発酵の金線連の逆相高速液体クロマトグラフを示す図であり、図4は、LcR金線連配糖体標準品の逆相高速液体クロマトグラフを示す図である。   The LcR gold-line continuous fermentation product and the unfermented gold-line string obtained in Example 1 were taken and analyzed using a reversed-phase high performance liquid chromatography column under the conditions in Example 2, respectively. The results are shown in FIG. 3 and FIG. 4, in which FIG. 3 is a diagram showing a reverse-phase high-performance liquid chromatograph of unfermented gold wires, and FIG. 4 is a standard product of LcR gold wires. It is a figure which shows the reverse phase high performance liquid chromatograph.

上記の分析結果を実施例2における前記回帰式にそれぞれ代入し、前記LcR金線連発酵産物および未発酵の金線連の金線連配糖体含量を、表2に示す。   The results of the above analysis are substituted into the regression equation in Example 2, and the LcR gold-line continuous fermentation product and the unfermented gold-line continuous glycoside content are shown in Table 2.

表2は、前記LcR金線連発酵産物および未発酵の金線連の金線連配糖体含量を示す。 Table 2 shows the content of the LcR gold continuous fermentation product and the unfermented gold wire continuous glycoside glycoside.

分析結果によると、未発酵の金線連に比べて、本発明が開示する前記LcR金線連発酵産物による金線連配糖体含量が大幅に向上したことが分かった。   According to the analysis results, it was found that the content of the gold-linked glycosides by the LcR gold-wire continuous fermentation product disclosed in the present invention was significantly improved as compared with the unfermented gold-wire continuous.

実施例4:金線連発酵産物は、高脂肪餌により誘発された肥満リスクを低下させることができる。   Example 4: Gold wire continuous fermentation products can reduce the risk of obesity induced by high fat diet.

複数のC57BL/6マウスを3群に分け、それぞれ環境条件に適応させるために1週間経過した後、異なる条件で12週間飼育し、その後、前記各群のマウスの体重変化を測定した結果を図5に示す。そのうち、第1群のマウスは、正常群として、正常餌を給餌する。第2群のマウスは、対照群として、肥満を誘発させるために高脂肪餌を給餌する。第3群のマウスに、高脂肪餌を給餌すると同時に実施例1で調製されたLcR金線連発酵産物を給餌し、当該LcR金線連発酵産物の投与量が660mg/kgである。   A plurality of C57BL / 6 mice were divided into 3 groups, and after one week had passed to adapt to the environmental conditions, they were raised for 12 weeks under different conditions, and then the changes in body weight of the mice in each group were measured. As shown in FIG. Among them, the first group of mice is fed with normal food as a normal group. The second group of mice, as a control group, is fed a high fat diet to induce obesity. The third group of mice is fed with the high fat diet and simultaneously with the LcR gold wire continuous fermentation product prepared in Example 1, and the dosage of the LcR gold wire continuous fermentation product is 660 mg / kg.

図5の結果によると、第2群のマウスの体重は第1群のマウスの体重より著しく重いことが分かった。高脂肪餌を給餌することで、マウスの体重を確実に増やせることができ、肥満モデルマウスが形成される。さらに、第2群および第3群のマウスを比べると、第3群のマウスの体重は第2群のマウスの体重より著しく軽いことは、本発明に開示されたLcR金線連発酵産物を給餌することにより、高脂肪餌により誘発された肥満を有効的に降下させることができた。   According to the results of FIG. 5, it was found that the weight of the second group of mice was significantly heavier than the weight of the first group of mice. By feeding a high fat diet, the weight of the mouse can be reliably increased, and an obese model mouse is formed. Furthermore, when the mice of the second group and the third group are compared, the weight of the mice of the third group is significantly lighter than the weight of the mice of the second group. By doing so, obesity induced by a high fat diet could be effectively reduced.

実施例5:金線連発酵産物は、体脂肪を減らすことができる。   Example 5: Gold wire continuous fermentation products can reduce body fat.

実施例4における前記各群のマウスを犠牲にし、その腎臓周囲脂肪組織と精巣周囲脂肪組織を採取し、重量を測定した結果を図6に示す。そのうち、図6Aは、各群のマウスの腎臓周囲脂肪組織重量を示す図で、図6Bは、各群のマウスの精巣周囲脂肪組織重量を示す図である。   FIG. 6 shows the results of sacrificing the perirenal adipose tissue and peri-testicular adipose tissue and measuring the weight of each group of mice in Example 4 sacrificed. 6A is a diagram showing the peri-renal adipose tissue weight of each group of mice, and FIG. 6B is a diagram showing the peri-testicular adipose tissue weight of each group of mice.

図6の結果によると、第1群のマウスの腎臓周囲脂肪組織および精巣周囲脂肪組織の重量はともに第2群のマウスより著しく軽いことがわかり、つまり、高脂肪餌を給餌することで、マウスの体重を確実に増やすことができる。さらに、第2群および第3群を比較すると、第2群のマウスの腎臓周囲脂肪組織および精巣周囲脂肪組織の重量に比べ、第3群のマウスの腎臓周囲脂肪組織および精巣周囲脂肪組織の重量はともに著しく低下することにより、本発明に開示されたLcR金線連発酵産物を給餌することで、内臓脂肪の蓄積量を有効的に降下することが分かった。   According to the results of FIG. 6, it can be seen that the weight of the perirenal and peritesticular adipose tissues of the first group of mice is significantly lighter than that of the second group of mice, that is, by feeding a high fat diet, You can definitely increase your weight. Further, when comparing the second group and the third group, the weight of the perirenal adipose tissue and the testicular adipose tissue of the third group of mice compared to the weight of the perirenal adipose tissue and peritesticular adipose tissue of the second group of mice. It has been found that the amount of visceral fat accumulated can be effectively reduced by feeding the LcR gold wire continuous fermentation product disclosed in the present invention.

さらに、上記各群のマウスの脂肪組織重量によりそれぞれの体脂肪組織含量を推論した結果は、図7に示すように、第2群のマウスの脂肪組織含量は第1群のマウスより著しく高いことから、第2群のマウスが、確実に肥満モデルマウスになるとともに、その体脂肪が増加したことが分かった。また、前記第3群のマウスの体脂肪組織含量は第2群のマウスより著しく低いことから、本発明に開示されたLcR金線連発酵産物を給餌する場合、体脂肪を有効的に降下できることが分かった。   Furthermore, as a result of inferring the body fat tissue content from the fat tissue weight of each group of mice as described above, as shown in FIG. 7, the fat tissue content of the second group of mice is significantly higher than that of the first group of mice. Thus, it was found that the second group of mice surely became an obese model mouse and that its body fat increased. In addition, since the body fat tissue content of the third group of mice is significantly lower than that of the second group of mice, when feeding the LcR gold line continuous fermentation product disclosed in the present invention, body fat can be effectively reduced. I understood.

実施例6:金線連発酵産物は、高脂肪餌により誘発される肥満を低減することができる。   Example 6: Gold wire continuous fermentation product can reduce obesity induced by high fat diet.

複数のC57BL/6マウスを3群に分け、環境条件に適応させるために1週間経過した後、異なる条件で8週間飼育し、その後、前記各群のマウスの重量を測定した結果を図8に示す。そのうち、第1群のマウスは、正常群として、正常水を給餌する。第2群のマウスは、対照群として、肥満誘発させるために濃度30%の糖水を給餌する。第3群のマウスは、濃度30%の糖水を給餌すると同時に本発明に開示されたLcR金線連発酵産物を給餌し、当該LcR金線連発酵産物の投与量が660mg/kgである。   A plurality of C57BL / 6 mice were divided into 3 groups, and after 1 week to adapt to environmental conditions, they were reared for 8 weeks under different conditions. Thereafter, the weight of each group of mice was measured and the results are shown in FIG. Show. Among them, the first group of mice is fed with normal water as a normal group. As a control group, the second group of mice is fed with 30% sugar water to induce obesity. The third group of mice is fed with 30% concentration of sugar water and simultaneously with the LcR gold wire continuous fermentation product disclosed in the present invention, and the dose of the LcR gold wire continuous fermentation product is 660 mg / kg.

図8の結果によると、第2群のマウスの体重は第1群のマウスの体重より著しく重いことが分かった。高濃度の糖水を給餌することで、マウスの肥満を確実に誘発することができることを示す。また、第3群のマウスの体重は第2群のマウスの体重より著しく軽いことは、本発明に開示されたLcR金線連発酵産物を給餌することにより、高濃度の糖水により誘発された肥満を有効的に降下することができた。   According to the result of FIG. 8, it was found that the weight of the second group of mice was significantly heavier than that of the first group of mice. It is shown that obesity in mice can be reliably induced by feeding a high concentration of sugar water. In addition, the weight of the mice in the third group is significantly lighter than the weight of the mice in the second group. Obesity induced by high-concentration sugar water by feeding the LcR gold line continuous fermentation product disclosed in the present invention. Was able to descend effectively.

実施例7:金線連発酵産物は、血糖を降下させることができる。   Example 7: Gold wire continuous fermentation product can lower blood sugar.

本実施例は、血糖値測定器で実施例6の前記各群のマウスの尾静脈血中グルコース濃度をそれぞれ測定する。ここで、まず前記各群のマウスの空腹時血糖値を測定してから、前記各群のマウスに葡萄糖を2.0g/kg給餌し、前記各群のマウスの血糖値をそれぞれ給餌後、30分、60分、90分および120分の間隔で再び測定した結果を、下記表3に示す。   In this example, the blood glucose level measuring device measures the glucose concentration in the tail vein blood of each group of mice of Example 6. Here, first, the fasting blood glucose levels of the mice of each group were measured, and then the mice of each group were fed with 2.0 g / kg of sucrose, and the blood glucose levels of the mice of each group were fed, respectively. Table 3 below shows the results measured again at intervals of minutes, 60 minutes, 90 minutes, and 120 minutes.

表3は、各群のマウスの葡萄糖負荷試験を示す。 Table 3 shows the sucrose tolerance test of each group of mice.

上記表3の結果によると、空腹時の第3群のマウスの血糖値は第2群のマウスの血糖値より著しく低いことが分かった。また、葡萄糖を給餌した後の前記各時点の第3群のマウスの血糖値も第2群のマウスの血糖値より低く、つまり、第3群のマウスは、インスリン抵抗性が引き起こされないことは、本発明に開示されたLcR金線連発酵産物を給餌することにより、インスリン抵抗性の発生を低減することができ、血糖を正常に調節することができた。   According to the results of Table 3 above, it was found that the blood glucose level of the third group of mice on an empty stomach was significantly lower than that of the second group of mice. In addition, the blood glucose level of the third group of mice at each time point after feeding sucrose is also lower than the blood glucose level of the second group of mice, that is, the mice of the third group do not cause insulin resistance. By feeding the LcR gold line continuous fermentation product disclosed in the present invention, it was possible to reduce the occurrence of insulin resistance and to regulate blood glucose normally.

実施例8:金線連発酵産物は、脂肪肝の形成を抑制することができる。   Example 8: Gold wire continuous fermentation product can suppress the formation of fatty liver.

実施例6における前記各群のマウスを犠牲にし、まず、前記各群のマウスの肝臓を取り、写真を撮って重量を測定した結果を、図9および図10に示す。そのうち、図10Aは、第1群のマウスの肝臓の写真であり、図10Bは、第2群のマウスの肝臓の写真であり、図10Cは、第3群のマウスの肝臓の写真である。   FIG. 9 and FIG. 10 show the results obtained by sacrificing the mice of each group in Example 6 and, first, taking the liver of each group of mice and taking a photo to measure the weight. 10A is a photograph of the liver of the first group of mice, FIG. 10B is a photograph of the liver of the second group of mice, and FIG. 10C is a photograph of the liver of the third group of mice.

その後、前記各群のマウスの肝臓をホルマリンで固定し、パラフィン包埋切片を行った後、ヘマトキシリン/エオシン染色法で染色を行い、脱水して片を密閉した後、光学顕微鏡により観察して写真撮影した結果を、図11に示す。そのうち、図11Aは、第1群のマウスの肝臓組織切片を染色した結果であり、図11Bは、第2群のマウスの肝臓組織切片を染色した結果であり、図11Cは、第3群のマウスの肝臓組織切片を染色した結果である。   Thereafter, the livers of the mice of each group were fixed with formalin, and after paraffin-embedded sections, stained with hematoxylin / eosin staining, dehydrated, sealed, and observed with an optical microscope. The photographed result is shown in FIG. 11A shows the result of staining the liver tissue section of the first group of mice, FIG. 11B shows the result of staining the liver tissue section of the second group of mice, and FIG. 11C shows the result of the third group of mice. It is the result of having dye | stained the liver tissue section | slice of a mouse | mouth.

また、前記各群のマウスの肝臓組織切片を4−ヒドロキシノネナール(4−hydroxynonenal)により免疫組織化学染色を行った結果は、図12に示す。そのうち、図12Aは、第1群のマウスの肝臓組織切片を染色した結果を示す図であり、図12Bは、第2群のマウスの肝臓組織切片を染色した結果を示す図であり、図12Cは、第3群のマウスの肝臓組織切片を染色した結果を示す図である。   Moreover, the result of having performed the immunohistochemical dyeing | staining of the liver tissue section | slice of the mouse | mouth of each said group by 4-hydroxynonenal (4-hydroxynonenal) is shown in FIG. 12A is a diagram showing the result of staining the liver tissue section of the first group of mice, and FIG. 12B is a diagram showing the result of staining the liver tissue section of the second group of mice. These are figures which show the result of having dye | stained the liver tissue section | slice of the 3rd group of mice | mouths.

図9乃至図12の結果を合わせて比較すると、第1群のマウスの肝臓は健康な肝臓であり、その色が朱色を呈し、ヘマトキシリン/エオシンにより染色された組織切片の色が比較的に明るい。第2群のマウスは、脂肪肝モデルマウスであるため、その肝臓は大量な脂肪を含有し、肝臓重量が第1群のマウスの肝臓重量より著しく高く、その色が白っぽくなって、脂肪組織空胞が目立ち、過酸化脂質の沈殿も比較的多くなって、高濃度糖水を給餌することから脂肪肝を形成し、肝臓重量が増やされ、肝臓に脂肪組織を蓄積させることを示す。第2群のマウスに比べ、第3群のマウスの肝臓重量が著しく低く、肝臓の色が第1群に著しく近づき、且つ脂肪組織空胞が比較的に目立たなく、沈着した過酸化脂質も比較的少ない。   Comparing the results of FIGS. 9 to 12 together, the liver of the first group of mice is a healthy liver, its color is vermilion, and the color of the tissue section stained with hematoxylin / eosin is relatively bright . Since the second group of mice is a fatty liver model mouse, the liver contains a large amount of fat, the liver weight is significantly higher than the liver weight of the first group of mice, the color becomes whitish, and the adipose tissue empty. It shows that cysts are conspicuous, lipid peroxide precipitation is relatively increased, and high concentration sugar water is fed to form fatty liver, liver weight is increased, and fatty tissue is accumulated in the liver. Compared with mice in group 2, liver weight of mice in group 3 is significantly lower, liver color is significantly closer to group 1, and adipose tissue vacuoles are relatively inconspicuous. Less.

以上のことから、本発明に開示されたLcR金線連発酵産物を給餌することにより、脂肪組織が形成されるとともに肝臓に蓄積されることを抑制し、高濃度糖水により誘発された脂肪肝を有効的に抑制することができる。   From the above, feeding the LcR gold-line continuous fermentation product disclosed in the present invention suppresses the formation of adipose tissue and accumulation in the liver, and prevents fatty liver induced by high-concentration sugar water. It can be effectively suppressed.

実施例9:金線連発酵産物は、糖尿病を治療することができる。   Example 9: Gold wire continuous fermentation product can treat diabetes.

実施例6に示す実施形態のように、複数のC57BL/6マウスを5群に分け、それぞれ環境条件に適応させるために1週間経過した後、異なる条件で8週間飼育する。そのうち、第1群のマウスは、正常群として、正常水を給餌する。第2群のマウスは、対照群として、脂肪肝を誘発させるために濃度30%の糖水を給餌する。第3群のマウスは、濃度30%の糖水を給餌すると同時に実施例1に調製されたLcR金線連発酵産物を給餌する。第4群のマウスは、濃度30%の糖水を給餌すると同時に実施例1に調製されたLrG金線連発酵産物を給餌する。第5群のマウスは、濃度30%の糖水を給餌すると同時に実施例1に調製されたLp金線連発酵産物を給餌する。   As in the embodiment shown in Example 6, a plurality of C57BL / 6 mice are divided into 5 groups, and after one week has passed to adapt to environmental conditions, they are raised for 8 weeks under different conditions. Among them, the first group of mice is fed with normal water as a normal group. As a control group, the second group of mice is fed with 30% sugar water to induce fatty liver. A third group of mice is fed with 30% strength sugar water and simultaneously with the LcR gold line continuous fermentation product prepared in Example 1. A fourth group of mice is fed with 30% strength sugar water and simultaneously with the LrG gold line continuous fermentation product prepared in Example 1. A fifth group of mice is fed with 30% strength sugar water and at the same time with the Lp gold wire continuous fermentation product prepared in Example 1.

8週間飼育した後、前記各群のマウスを犠牲にし、前記各群のマウスの肝臓を採取し、それぞれ凍結用包埋液により包埋切片にしてから、免疫組織染色を行い、前記各群のマウスの肝臓におけるインスリン受容体(insulin−receptor)およびグルコース輸送体(GLUT4)を観察する。図13および図14に示すように、図13A乃至図13Eは、それぞれ、前記各群のマウスの肝臓におけるインスリン受容体の免疫組織染色の結果を示す図である。図14A乃至図14Eは、それぞれ、前記各群のマウスの肝臓におけるグルコース輸送体の免疫組織染色の結果を示す図である。   After breeding for 8 weeks, the mice of each group were sacrificed, the livers of the mice of each group were collected, and each of the groups was embedded with a freezing embedding solution, and then subjected to immunohistochemical staining. Insulin-receptor and glucose transporter (GLUT4) in mouse liver are observed. As shown in FIGS. 13 and 14, FIGS. 13A to 13E are diagrams showing the results of immunohistochemical staining of insulin receptors in the liver of each group of mice. FIG. 14A to FIG. 14E are diagrams showing the results of immunohistochemical staining of glucose transporters in the liver of each group of mice.

図13および図14の結果によると、第2群のインスリン受容体は第1群のインスリン受容体より少なく、第3群から第5群のいずれか1群のインスリン受容体含量は、第1群のインスリン受容体含量に近づいている。また、第1群に比べ、第2群の肝臓組織切片における細胞で観察したグルコース輸送体は比較的少なく、第3群から第5群の細胞で観察したグルコース輸送体は、それぞれ、第2群よりはるかに多かった。したがって、本発明に開示された前記各金線連発酵産物は、それぞれ、糖尿病の治療または改善の作用を有する。   According to the results of FIGS. 13 and 14, the second group of insulin receptors is less than the first group of insulin receptors, and the insulin receptor content of any one of the third group to the fifth group is the first group. The insulin receptor content is approaching. In addition, the glucose transporters observed in the cells in the liver tissue section of the second group were relatively few as compared to the first group, and the glucose transporters observed in the cells of the third group to the fifth group were respectively the second group. Much more than that. Therefore, each said gold wire continuous fermentation product disclosed by this invention has an effect | action of the treatment or improvement of diabetes, respectively.

以上実施例の説明によると、本発明に開示された製造方法は、微生物による生産製造システムにより、低コストの方法で金線連発酵産物を大量生産及び製造することができ、かつ金線連発酵産物に大量な金線連配糖体を含有させることに基づいて、高脂肪または高糖により誘発された体重増加、脂肪肝、内臓脂肪の蓄積、血糖上昇または糖尿病などの疾患に対し、それぞれ、抑制または緩和作用を有することで、医薬組成物の有効成分または保健用食品として調製することができる。   As described above, according to the embodiments, the production method disclosed in the present invention is capable of mass production and production of a continuous wire fermentation product by a low cost method using a production system using microorganisms. Based on the inclusion of large amounts of gold-linked glycosides in the product, for diseases such as weight gain, fatty liver, visceral fat accumulation, elevated blood sugar or diabetes induced by high fat or high sugar, respectively By having an inhibitory or mitigating action, it can be prepared as an active ingredient of a pharmaceutical composition or a food for health.

上記のように、本発明を各実施例によって詳しく説明したが、当業者が、本発明の実施例に対して為された簡単な修飾や変化の全ては、本発明の特許請求の範囲内に含まれるものとする。   As described above, the present invention has been described in detail with reference to the embodiments. However, all simple modifications and changes made by those skilled in the art to the embodiments of the present invention are within the scope of the claims of the present invention. Shall be included.

Claims (3)

金線連発酵産物の製造方法において、
乳酸菌と金線連培地とを発酵反応させるステップaと、
ステップaに得られた発酵液により金線連発酵産物を得るステップbとを含み、
前記ステップaにおける前記乳酸菌がラクトバチルス・カゼイ・サブスピーシーズ・ラムノサス(Lactobacillus casei subsp. Rhamnosus)、ラクトバチルス・ラムノサス GG菌(Lactobacillus rhamnosus G.G.)及びラクトバチルス・プランタラム(Lactobacillus plantarum)からなる群から選択されたものである、
金線連発酵産物の製造方法。
In the method for producing the gold-line continuous fermentation product,
A step of fermenting a lactic acid bacterium and a gold wire continuous medium;
Including step b of obtaining a continuous fermented gold wire product from the fermentation liquid obtained in step a ,
The lactic acid bacteria in Step a are Lactobacillus casei subsp. Rhamnosus (Lactobacillus casei subsp. Rhamnosus), Lactobacillus rhamnosus g. Selected from the group,
A method for producing gold-line continuous fermentation products.
前記ステップaにおける行われる発酵反応の条件は、温度が25〜42℃であり、pH値が4.0〜7.0であり、撹拌速度が0〜100rpmである、請求項1に記載の金線連発酵産物の製造方法。Conditions of the fermentation reaction performed in the step a, the temperature is 25 to 42 ° C., pH value is 4.0 to 7.0, stirring speed is 0 to 100 rpm, according to claim 1 A method for producing gold-line continuous fermentation products. 前記ステップbにおける前記発酵液に対して滅菌および遠心分離を行うことで、前記金線連発酵産物を得る、請求項1または2に記載の金線連発酵産物の製造方法。 3. The method for producing a continuous wire fermentation product according to claim 1 or 2 , wherein the fermented gold solution is obtained by sterilizing and centrifuging the fermentation broth in step b.
JP2013260261A 2013-10-24 2013-12-17 Gold wire continuous fermentation product, production method and use thereof Expired - Fee Related JP5845240B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TW102138531 2013-10-24
TW102138531A TW201515649A (en) 2013-10-24 2013-10-24 Anoectochilus spp. fermentation product and its manufacturing method and application

Publications (2)

Publication Number Publication Date
JP2015080477A JP2015080477A (en) 2015-04-27
JP5845240B2 true JP5845240B2 (en) 2016-01-20

Family

ID=53011426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013260261A Expired - Fee Related JP5845240B2 (en) 2013-10-24 2013-12-17 Gold wire continuous fermentation product, production method and use thereof

Country Status (2)

Country Link
JP (1) JP5845240B2 (en)
TW (1) TW201515649A (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2746079B2 (en) * 1993-09-07 1998-04-28 正和薬品株式会社 Blood glucose elevation inhibitor and lipid metabolism improver
JP3591166B2 (en) * 1996-10-28 2004-11-17 正和薬品株式会社 Anti-obesity agent
JPH1192492A (en) * 1997-09-19 1999-04-06 Seiwa Yakuhin Kk Method for separating 3-o-glucopyranosyl-gamma-butyrolactone
JP2002145894A (en) * 2000-11-10 2002-05-22 Seiwa Yakuhin Kk METHOD FOR PRODUCING 3,4-DIHYDROXYBUTYRIC ACID DERIVATIVE AND 3-HYDROXY-gamma-BUTYROLACTONE DERIVATIVE
JP2002114693A (en) * 2001-08-31 2002-04-16 Seiwa Yakuhin Kk Hypoglycemic agent
TWI369207B (en) * 2007-03-29 2012-08-01 Univ China Medical Aqueous extracts of anoectochilus spp. and uses of the same
TW201023862A (en) * 2008-12-31 2010-07-01 Univ China Medical Pharmaceutical compositions and extracts containing kinsenoside for inhibiting activation of macrophage, inhibiting formation of osteoclasts, inhibiting function of osteoclasts, and/or activating osteoblasts and uses of the same
CN102823655B (en) * 2012-08-31 2013-11-06 福建省农业科学院农业生物资源研究所 Preparation method of anoectochilus formosanus plant protein lactic acid beverage
TWI484973B (en) * 2012-11-29 2015-05-21 New Bellus Entpr Co Ltd Mixture from fermentation of anoectochilus formosanus hayata by microorganism and use thereof
CN103271244B (en) * 2013-05-13 2014-04-09 仝荣 Preparation method of pig feed zymophyte additive

Also Published As

Publication number Publication date
JP2015080477A (en) 2015-04-27
TW201515649A (en) 2015-05-01
TWI473616B (en) 2015-02-21

Similar Documents

Publication Publication Date Title
KR101809172B1 (en) Composition for preventing, improving or treating metabolic disease comprising Akkermansia muciniphila strain or its culture broth cultivated in medium without mucin as effective component
KR101912481B1 (en) Composition, glucose metabolism-improving agent, and method for improving glucose metabolism
KR101912774B1 (en) Composition comprising a strain having formic acid producing ability for the preventing or treatment of obesity, or obesity-realated metabolic syndrome
KR101614574B1 (en) Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange
US20210353697A1 (en) Composition comprising molokhia extract as active ingredient for improving gut microbiome or for alleviating, preventing, or treating intestinal inflammation, leaky gut syndrome, obesity, or metabolic disease
JP6445686B2 (en) Anti-diabetic effect of dipenoside 75
JP2009249320A (en) Obesity- and diabetes-ameliorating agent
KR101549746B1 (en) Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders
JP2020511434A (en) Composition for preventing or treating obesity or metabolic syndrome caused by obesity, comprising formic acid or a pharmaceutically acceptable salt thereof as an active ingredient
KR101446528B1 (en) Vinegar Composition Fermented with Black Garlic and Preparation Method Thereof
JP2010111646A (en) Treating agent for ulcerative colitis
JP5845240B2 (en) Gold wire continuous fermentation product, production method and use thereof
KR101350046B1 (en) Vinegar composition fermented with herbal extracts and preparation method thereof
JP2006335725A (en) Composition for improving bloodstream
KR101047796B1 (en) Cold grass extract having an effect of improving insulin resistance and a product containing the same as an active ingredient
US20170209511A1 (en) Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients
KR100615981B1 (en) Yogurt composition for the control of a blood glucose
JP2019108364A (en) Nutritive composition
JP6351019B2 (en) Appetite suppression composition
JP6173850B2 (en) Muscle bulking agent, muscle bulking agent when used together with exercise, and food and drink for muscle weight gain
KR102158337B1 (en) Composition for preventing, ameliorating or treating fatty liver disease comprising vinegar of Kalopanax septemlobus as effective component
KR20100041049A (en) Compositions for reducing cholesterol comprising extracts of vaccinium oldhami miquel leaf as an active ingredient
WO2020031952A1 (en) Composition and method for suppressing increase in blood glucose level
KR20220102280A (en) A composition for improvementing, preventing or treating inflammatory bowel disease or leaky gut syndrome comprising roast garlic
KR20190131315A (en) A composition for recovery after surgical comprising extracts of Tenebrio molitor

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151120

R150 Certificate of patent or registration of utility model

Ref document number: 5845240

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees